No supplier or customer ties in PEPG's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Nothing on the wire mentions PEPG yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How PEPG has moved on past release days vs its typical ±5.2% day, and how often it closed up. Computed from daily closes — not a forecast.